ECM
JAZZ icon

Estuary Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Estuary Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-106,387
Closed -$18.1M – 27
2025
Q4 		$18.1M Sell
106,387
-256,760
-71% -$39.4M 3.22% 16
2025
Q3 		$47.9M Sell
363,147
-74,496
-17% -$8.94M 8.5% 3
2025
Q2 		$46.4M Buy
437,643
+127,893
+41% +$13.9M 9.05% 6
2025
Q1 		$38.5M Buy
309,750
+77,233
+33% +$10.1M 9.33% 5
2024
Q4 		$28.6M Sell
232,517
-29,040
-11% -$3.42M 8.37% 7
2024
Q3 		$29.1M Sell
261,557
-5,887
-2% -$645K 7.82% 8
2024
Q2 		$28.5M Buy
267,444
+53,994
+25% +$5.94M 9.2% 5
2024
Q1 		$25.7M Buy
213,450
+85,779
+67% +$10.5M 10.44% 4
2023
Q4 		$15.7M Buy
+127,671
New +$15.9M 9.5% 2

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Estuary Capital Management's JAZZ Position: Q1 2026 in Review

Estuary Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 106,387 shares — an estimated $18.1M sold.

Estuary Capital Management first reported a position in JAZZ in Q4 2023 and held it in 9 quarters. The position peaked at $47.9M in Q3 2025. 573 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • Estuary Capital Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Estuary Capital Management sold 106,387 Jazz Pharmaceuticals shares in Q1 2026, an estimated $18.1M.
  • Estuary Capital Management first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 9 quarters.
  • Estuary Capital Management's Jazz Pharmaceuticals position peaked at $47.9M in Q3 2025.
  • 573 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Estuary Capital Management's 13F filing for Q1 2026, filed 15 May 2026.